push tirzepatide Switch to in T2D More Effective Than Upping Dulaglutide Dose Compounded Tirzepatide vs. Semaglutide -

Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications

Rapid weight loss feels like it should require metabolic support

The most common side effects of GLP-1s are nausea, vomiting, diarrhea, and abdominal pain

Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies

Since retatrutide is still in clinical trials, semaglutide remains the more proven and accessible option